Category Suggestions for Question Creation:
- Allergy and Immunology (AI)
- Biostatistics and Epidemiology (BE)
- Cardiovascular Medicine (V)
- Critical Care (CC)
- Dermatology (DM)
- Ear, Nose, and Throat (ENT)
- Endocrinology and Metabolism (EM)
- Ethics and Professionalism (EP)
- Gastroenterology and Hepatology (GI)
- Genetics and Genomics (GN)
- Geriatrics (GER)
- Hematology (HM)
- History of Medicine (HM)
- Infectious Disease
- Men's Health
- Nephrology (NP)
- Neurology (NR)
- Oncology (ON)
- Opthalmology (OP)
- Pharmacology (PH)
- Pulmonary Medicine (PM)
- Rheumatology (RM)
- Psychiatry (PSY)
- Travel Medicine
- Women's Health (WH)
Example Questions:
Question #1: This protein is low or deficient in Type I hereditary angiodema.
Answer: What is C1 inhibitor protein?
Fun Fact: Cinryze, a pharmaceutical grade C1 inhibitor, was approved for HAI in the U.S. in 2008 after having been available in Europe for decades.
Source: Cinryze. U.S. Food and Drug Administration. 12 July 2017. Archived from original on 22 July 2017. Retrieved 20 April 2020.
Question #2: This disease is caused by a deficit in nicotinamide adenine dinucleotide phosphate (NADPH) oxidase and involves recurrent bacterial and fungal infections.
Answer: What is chronic granulomatous disease?
Fun Fact: It is also known as Bridges-Good syndrome and Quie Syndrome. Difficulty forming the reactive oxygen compounds (most importantly the superoxide radical due to defective phagocyte NADPH oxidase) leads to granuloma formation.
Source: Heyworth, PG, Cross, AR, Curnette, JT. October 2023. Chronic granulomatous disease. Current opinion in Immunology. 15 (5): 578-84.